Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)
Tracking Information | |
---|---|
First Received Date ICMJE | March 28, 2005 |
Last Updated Date | August 21, 2007 |
Start Date ICMJE | March 2005 |
Primary Completion Date | |
Current Primary Outcome Measures ICMJE |
|
Original Primary Outcome Measures ICMJE | Same as current |
Change History | Complete list of historical versions of study NCT00106600 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures ICMJE | |
Original Secondary Outcome Measures ICMJE | |
Current Other Outcome Measures ICMJE | |
Original Other Outcome Measures ICMJE | |
Descriptive Information | |
Brief Title ICMJE | Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) |
Official Title ICMJE | A Phase I/II Study of Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) |
Brief Summary | The goal of this study is to find the safest dose of Pixantrone (BBR 2778) that can be given to patients with Acute Myelogenous Leukemia (AML). After the safest dose is found, up to an additional 86 patients will be enrolled. During this part of the study, the safety and effectiveness will be evaluated. |
Detailed Description | This is an open label, single center, phase I/II study of pixantrone in patients with refractory AML. Pixantrone will be administered for three consecutive days on days 1, 2 and 3 of each 21-day cycle, for up to two cycles. The study has 2 parts; phase I and phase II. In the phase I part of the study, the maximum tolerated dose (MTD) for pixantrone as a single agent in patients with refractory AML will be determined. In the phase II part of the study, up to an additional 86 patients will be treated at the MTD to assess disease response. |
Study Type ICMJE | Interventional |
Study Phase | Phase 1 Phase 2 |
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Condition ICMJE | Acute Myelogenous Leukemia |
Intervention ICMJE | Drug: Pixantrone IV infusion |
Study Arm (s) | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
Recruitment Information | |
Recruitment Status ICMJE | Completed |
Enrollment ICMJE | 119 |
Completion Date | March 2007 |
Primary Completion Date | |
Eligibility Criteria ICMJE | Inclusion Criteria:
Eligible patients include the following:
Exclusion Criteria:
|
Gender | Both |
Ages | 18 Years and older |
Accepts Healthy Volunteers | No |
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
Location Countries ICMJE | United States |
Administrative Information | |
NCT Number ICMJE | NCT00106600 |
Other Study ID Numbers ICMJE | PIX109 |
Has Data Monitoring Committee | |
Responsible Party | |
Study Sponsor ICMJE | Cell Therapeutics |
Collaborators ICMJE | |
Investigators ICMJE | |
Information Provided By | Cell Therapeutics |
Verification Date | August 2007 |
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |